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A B S T R A C T
Tumor-associated macrophages (TAMs) have important roles in the angiogenesis and tumor immuno-
suppression of various cancers, including esophageal squamous cell carcinomas (ESCCs). To elucidate the
roles of TAMs in ESCCs, we compared the gene expression proﬁles between human peripheral blood
monocyte-derived macrophage-like cells (Macrophage_Ls) and Macrophage_Ls stimulated with condi-
tioned medium of the TE series human ESCC cell line (TECM) (TAM_Ls) using cDNA microarray analysis.
Among the highly expressed genes in TAM_Ls, we focused on neural cell adhesion molecule (NCAM). NCAM
knockdown in TAM_Ls revealed a signiﬁcant decrease of migration and survival via a suppression of PI3K-
Akt and ﬁbroblast growth factor receptor 1 (FGFR1) signaling. Stimulation by TECM up-regulated the level
of FGFR1 in Macrophage_Ls. Recombinant human ﬁbroblast growth factor-2 (rhFGF-2) promoted the mi-
gration and survival of TAM_Ls and TE-cells through FGFR1 signaling. Our immunohistochemical analysis
of 70 surgically resected ESCC samples revealed that the up-regulated FGF-2 in stromal cells, including
macrophages, was associated with more aggressive phenotypes and a high number of inﬁltrating M2
macrophages. These ﬁndings may indicate a novel role of NCAM- and FGF-2-mediated FGFR1 signaling
in the tumor microenvironment of ESCCs.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The interaction between cancer cells and stromal cells pro-
duces a cancer-speciﬁc microenvironment for tumor progression [1].
Macrophages, one of the most important components of a tumor
microenvironment, are divided into two phenotypes from an on-
cologic viewpoint: a tumor-suppressive (M1) phenotype and a
tumor-supportive (M2) phenotype [2]. Tumor-associated mac-
rophages (TAMs) polarize mainly into the M2 phenotype depending
on microenvironmental factors [3,4]. M2 macrophages generally
exhibit an interleukin (IL)-10high, IL-12low phenotype and demon-
strate high expression of CD163 (a hemoglobin scavenger receptor)
and CD204 (a class A macrophage scavenger receptor) [5,6]. Inﬁl-
trations of TAMs with the M2 phenotype correlate with poor
prognosis in patients with various types of tumor [7–11].
Esophageal cancer is the sixth leadingcauseof cancer-relateddeath
and theeighthmost commoncancerworldwide.Anestimated455,800
new esophageal cancer cases and 400,200 deaths were recorded in
2012 worldwide [12]. Recent epidemiological studies reported that
the number of esophageal adenocarcinomas has tended to increase
in not only Western countries but also in Asian countries. However,
squamous cell carcinoma of the esophagus (ESCC) still accounts for
most of the esophageal carcinomas in the Asian countries, including
Japan. Various factors, e.g., alcohol and smoking, are considered to
present a risk of ESCC development [13,14].
We reported that the number of inﬁltrating CD204+ mac-
rophages in ESCC tissues exhibits a signiﬁcant correlation with
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clinicopathological factors and prognosis [10]. In vitro studies dem-
onstrated that bone marrow-derived peripheral blood monocyte
(PBMo)-derived macrophage-like cells (Macrophage_Ls) stimu-
lated with conditioned media of ESCC cells (TECM) had signiﬁcantly
more enhanced M2-like genes than Macrophage_Ls, such as IL-10,
CD163, CD204, VEGFA, MMP2 and MMP9 [15]. We also analyzed the
up-regulated genes, including cysteine-rich angiogenic inducer 61
(Cyr61) and growth differentiation factor 15 (GDF15), using a cDNA
microarray betweenMacrophage_Ls treatedwith andwithout TECM.
The up-regulation of Cyr61 and GDF15 exhibited a signiﬁcant pos-
itive correlation with inﬁltrating CD204+ TAMs in human ESCC
samples [15,16]. In the present study, among the highly expressed
genes inMacrophage_Ls stimulatedwith TECM (TAM_Ls), we focused
on neural cell adhesion molecule (NCAM).
NCAM is one of the immunoglobulin superfamily molecules iso-
lated from chicken nerve retina cells [17–19]. NCAM has three major
isoforms created by alternative splicing, and the extracellular part
is comprised of ﬁve Ig modules and two ﬁbronectin type III ho-
mology modules. NCAM is associated with neurite outgrowth and
intracellular adhesion through homophilic and heterophilic inter-
actions in the nervous system [20]. NCAM expression has been
reported not only in nerve cells but also in various non-neural cell
types, including monocytes [21]. NCAM is also involved in the pro-
gression of various types of cancer [22–25]. However, the signiﬁcance
of NCAM expression in TAMs has not been established, and here
we investigated a potential role of NCAM expressed in TAMs in the
ESCC microenvironment.
Materials and methods
Cell cultures and reagents
Three ESCC cell lines (TE-8, TE-9 and TE-15) were obtained from the RIKEN
BioResource Center (Tsukuba, Japan). The individuality of the TE series ESCC cell lines
was conﬁrmed by a short tandem repeat analysis at RIKEN and at the Cell Re-
source Center for Biomedical Research, Institute of Development, Aging and Cancer,
Tohoku University (Sendai, Japan). Human peripheral bloodmononuclear cells (PBMCs)
were obtained from healthy volunteer donors who providedwritten informed consent.
We puriﬁed CD14+ PBMos from the PBMCs by positive selection using an autoMACS
Pro Separator (Miltenyi Biotec, Bergisch Gladbach, Germany).
The PBMos were treated with macrophage-colony stimulating factor (M-CSF,
25 ng/mL; R&D Systems, Minneapolis, MN) for 6 d to induceMacrophage_Ls and then
exposed to the conditioned media of the TE series ESCC cell lines (TECMs) for 2 d
to induce TAM_Ls as described [15]. All cells were mycoplasma negative as dem-
onstrated by a Venor® GeMClassicMycoplasma Detection kit (Minerva Biolabs, Berlin,
Germany). The following selective inhibitors and recombinant protein were used:
PI3K inhibitor (LY294002, 20 μM; Cell Signaling Technology, Beverly, MA); FGFR1
inhibitor (SU5402, 50 μM; Santa Cruz Biotechnology, Dallas, TX); human recombi-
nant basic ﬁbroblast growth factor (rhFGF-2, 5–20 ng/mL; R&D Systems).
Tissue samples
A total of 70 human ESCC tissue samples were examined in our study as de-
scribed [10]. Informed consent for the use of the tissue samples was obtained from
all patients, and the study was approved by the Kobe University Institutional Review
Board. We analyzed histological and clinicopathological information using the Jap-
anese Classiﬁcation of Esophageal Cancer proposed by the Japan Esophageal Society
and the TNM classiﬁcation of the Union for International Cancer Control [26,27].
Immunohistochemistry
Antigen retrieval of 10% formalin-ﬁxed and paraﬃn-embedded tissues was heat-
induced in citrate buffer, pH 6.0. Immunohistochemistrywas performed using EnVision
Dual Link System-HRP, 3,3′-diaminobenzidine (Dako Cytomation, Glostrup, Denmark).
The primary antibodies are listed in Supplementary Table S1. The FGF-2 immuno-
reactivity of the cancer nests and stroma was assessed separately. We evaluated the
immunohistochemical staining intensity of FGF-2 in the cancer nests as qualitative
scores: 0 (negative), 1 (weak), 2 (intermediate) and 3 (strong). We assessed the pro-
portion of immune-positive stromal cells in the stroma by counting the number of
these cells per high-power ﬁeld as low (<30) and high (≥30) using the correspond-
ing normal squamous epithelia as a positive control. The immunoreactivity of the
cancer nests was considered high with a score of 2 or 3. We also determined the
correlations between the expression of FGF-2 and clinicopathological parameters
and the inﬁltrating macrophage phenotypes.
Immunoﬂuorescence
Cultured cells were ﬁxed with methanol (purity > 99.8%; Wako, Osaka, Japan).
The primary and secondary antibodies are listed in Supplementary Table S1. Nuclei
and F-actin were stained with DAPI (Wako) and phalloidin (P1951, Sigma-Aldrich,
St. Louis, MO), respectively. These samples were observed under a laser-scanning
microscope (LSM700, Carl Zeiss, Oberkochen, Germany) and analyzed using ZEN 2009
software (Carl Zeiss).
Reverse transcription-polymerase chain reaction (RT-PCR) and quantitative
RT-PCR
We extracted total RNA from cultured cells using the RNeasy Mini Kit (Qiagen,
Hilden, Germany). RT-PCR ampliﬁcations of NCAM and the control gene GAPDH were
performed. We conducted the quantitative RT-PCR ampliﬁcations of NCAM and the
control gene GAPDH using the ABI StepOne Real-time PCR system (Applied Biosystems,
Foster City, CA). The primers listed in Supplementary Table S2 were designed as
described [28,29].
Knockdown of NCAM by small interfering RNA (siRNA) and human
phosphoprotein array
First, 1 × 106 Macrophage_Ls were transfected at 20 nM concentrations for 6 h
with siRNA for NCAM (Sigma) or negative control (NC, S1C-001, Sigma) using
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA). The sequences of the siRNA tar-
geting NCAM are as follows: sense, 5′-GAGGUAUUUGCCUAUCCCAtt-3′; antisense, 5′-
UGGGAUAGGCAAAUACCUCtt-3′. Transfected cells were then exposed to TECM for
2 d to induce TAM_Ls and cultured for 24 h in serum-free Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM, Wako). The cell lysates were collected and applied to a Proteome
Proﬁler Human Phosphokinase Array Kit (R&D Systems).
Enzyme-linked immunosorbent assay (ELISA)
Here, 5 × 106 TE cells were seeded on 100-mm dishes ﬁlled with DMEM supple-
mented with 10% human AB serum (Lonza, Walkersville, MD). Then, 1 × 106
Macrophage_Ls and TAM_Ls were incubated on six-well plates ﬁlled with DMEM
supplemented with 10% human AB serum. After 2 d, the cells were collected and
applied to a Quantikine ELISA Human FGF basic immunoassay (R&D Systems). We
determined the optical density using a Microplate Reader Inﬁnite 200 PRO (Tecan,
Männedorf, Switzerland).
Western blotting
Cells were lysed in a cell lysis buffer (50 mM Tris–HCl pH 7.5, 125mMNaCl, 0.1%
Triton X-100 and 5 mM EDTA) or NP40 cell lysis buffer (Thermo Fisher Scientiﬁc,
Waltham, MA). The resulting lysates were separated on 5 to 20% sodium dodecyl
sulfate polyacrylamide gels and blotted with primary antibodies. The primary and
secondary antibodies are listed in Supplementary Table S1. The blots were then probed
with ImmunoStar Reagents (Wako).
Transwell migration assay and cell survival assay
Transwell migration assay
1 × 105 cells were detachedwith Accutase (Innovative Cell Technologies, San Diego,
CA) or trypsin-EDTA (Thermo Fisher). The cells were then seeded on Transwell cell
culture inserts (8-μm pore size ﬁlter, BD Falcon, Lincoln Park, NY) ﬁlled with serum-
free DMEM for 24 h. The cell inserts were then set on the 24-well plates ﬁlled with
DMEM supplemented with 1% human AB serum. After a period of 24 h, migrated
cells on the underside of the membrane were stained with Diff-Quik (Sysmex, Kobe,
Japan) and counted.
Cell survival assay
1 × 104 detached cells were seeded on 96-well plates (BD Falcon) ﬁlled with
serum-free DMEM. After 24 h, we applied CellTiter 96 AQueous One Solution Reagent
(Promega, Madison, WI). We determined the optical density of each well using the
microplate reader.
Statistical analysis
We used χ2-tests to analyze the relationships between clinicopathological factors
and the immunohistochemical results. The statistical signiﬁcance of differences in
the in vitro assay results was evaluated by two-sided Student’s t-test. Signiﬁcance
was set at a p-value < 0.05. The statistical analyses were performed with SPSS
Statistics ver. 22 (IBM, Chicago, IL).
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Results
NCAM expression in Macrophage_Ls is up-regulated by conditioned
media of ESCC cell lines
We ﬁrst conﬁrmed the induction of NCAM in TAM_Ls. NCAM
mRNA and protein expression was signiﬁcantly induced by TECM
(TE-8, TE-9 and TE-15) compared with the Macrophage_Ls
(Fig. 1A–C). The expression of NCAM in the TAM_Ls was con-
ﬁrmed by the molecular weight 180 kDa (Fig. 1C). As the NCAM
induction was most effective by TE-9CM, we focused on the
Macrophage_Ls stimulated with TE-9CM (TAM_L_TE-9). The up-
regulated NCAM was identiﬁed mainly in the cell membrane of
TAM_L_TE-9 (Fig. 1D).
In contrast, the NCAM induction inM2macrophages was not pro-
duced by the stimulation of IL-4 and IL-13 (Suppl. Fig. S1). We
previously demonstrated that TECM induced the M2 phenotype in
the 12-O-tetradecanoylphorbol 13-acetate (TPA)-treated human acute
monocytic leukemia cell line (THP-1) macrophage-like cells
(Macrophage_Ls_THP-1) [10]. In the present study, exposure to TECM
signiﬁcantly induced NCAM expression in Macrophage_Ls_THP-1
(Suppl. Fig. S2). Morphologically, a portion of the lamellipodia was
co-localized with F-actin (phalloidin) and NCAM in the TAM_Ls_TE-
9, implying that NCAM was involved in the migration of TAM_Ls
(Fig. 1E).
NCAM is involved in TAM_L migration and survival through
PI3K-Akt signaling
We then assessed the migration and survival of TAM_Ls. Expo-
sure to TE-9CM signiﬁcantly promoted the migration and survival
of Macrophage_Ls (Fig. 2A). We next examined the role of NCAM
in TAM_L_TE-9 by using siRNA. NCAM silencing was conﬁrmed by
RT-PCR, quantitative RT-PCR and western blotting (Suppl. Fig. S3).
NCAM silencing resulted in signiﬁcant decreases in the migration
and survival of TAM_Ls_TE-9 (Fig. 2B).
Next, we conducted a phospho-kinase antibody array to assess
the changing levels of phosphorylated proteins by NCAM knock-
down. Interestingly, the silencing of NCAM in TAM_Ls_TE-9
suppressed PI3K-Akt (Thr308) and p70 S6K (Thr421/Ser424), namely
PI3K-Akt signaling (Fig. 2C). Moreover, exposure to TECM (TE-8, TE-9
and TE-15) activated PI3K-Akt signaling in Macrophage_Ls (Fig. 2D).
In addition, LY294002 (20 μM) signiﬁcantly inhibited the migra-
tion and survival of TAM_Ls_TE-9 (Fig. 2E).
NCAM- and FGF-2-mediated FGFR1 signaling regulated the
expression of phosphorylated FGFR1 in TAM_Ls
The interaction between NCAM- and ﬁbroblast growth factor-2
(FGF-2)-mediated ﬁbroblast growth factor receptor 1 (FGFR1) sig-
naling is known to induce a speciﬁc cellular response in HeLa cells
[30]. However, their expressions and interactions in the ESCC mi-
croenvironment, includingmacrophages, are not clearly understood.
In the FGFR family, FGFR1 is expressed on human monocytes [31].
We thus investigated the functional role of FGFR1 signaling in
TAM_Ls. Our immunoﬂuorescence protocol demonstrated that NCAM
was co-localized with FGFR1 at the cell membrane in TAM_L_TE-9
(Fig. 3A). Interestingly, NCAM silencing suppressed FGFR1 and its
phosphorylation in TAM_Ls_TE-9 (Fig. 3B). Up-regulation of FGFR1
expression was induced in all types of TAM_Ls, and FGFR1 phos-
phorylation was also observed in the TAM_Ls (TE-9 and TE-15)
(Fig. 3C).
Weanalyzed thesecretionof FGF-2 fromESCCcell linesandTAM_Ls
by ELISA. The secreted FGF-2 levels in TE-8, TE-9 and TE-15 were
20.58 ± 2.38 pg/mL, 12.74 ± 2.67 pg/mL and 0.98 ± 0.35 pg/mL,
respectively. In contrast, FGF-2 secreted by TAM_Ls was not
detected (Fig. 3D).
We then investigated the effect of FGF-2 on TAM_Ls. Interest-
ingly, rhFGF-2 treatment resulted in phosphorylation of FGFR1 and
the downstream signaling, such as PI3K-Akt and MEK1/2-Erk1/2.
The phosphorylation level of the downstream signaling was main-
tained for up to 1 h in TAM_Ls_TE-9 (Fig. 3E). Pretreatment with
SU5402 signiﬁcantly inhibited the phosphorylation of FGFR1, Akt
and Erk1/2 in TAM_Ls_TE-9 (Fig. 3E). In addition, TAM_Ls_TE-9 sig-
niﬁcantly promoted migration and survival by FGF-2, which was
inhibited by SU5402 (Fig. 3F).
FGF-2-mediated FGFR1 signaling is involved in the migration and
survival of ESCC cells
We next investigated the effect of FGF-2/FGFR1 signaling on ESCC
cell lines. The expression of FGFR1 was detected in TE-8, TE-9 and
TE-15 (Fig. 4A). Treatment with rhFGF-2 activated MEK1/2-Erk1/2
signaling in TE-9. Pretreatment with SU5402 signiﬁcantly inhib-
ited MEK1/2-Erk1/2 phosphorylation in TE-9 (Fig. 4B). FGF-2
signiﬁcantly promoted the migration and survival of TE-9, which
were inhibited by SU5402 (Fig. 4C).
Up-regulated FGF-2 in stromal cells, including macrophages, is
associated with more aggressive phenotypes and an increased
number of inﬁltrating M2 macrophages
FGF-2 overexpression has been reported in esophageal cancer,
and this overexpression may lead to poor prognosis [32]. In con-
trast, Sugiura et al. reported a negative correlation between FGF-2
expression and clinical prognosis limited to ESCC [33]. We thus in-
vestigated the relationships between the expression levels of FGF-2
and clinicopathological parameters including M2 macrophage
markers in ESCCs.
We ﬁrst conﬁrmed the expression of FGF-2 by demonstrating
immunoﬂuorescencemainly in the cytoplasm and nucleus of CD204+
TAM_Ls_TE-9 (Fig. 4D). Interestingly, the double immunoﬂuores-
cence analysis demonstrated that the FGF-2 was expressed not only
in cancer cells but also in cancer stromal cells (including CD204+
TAMs) in human ESCC tissues (Fig. 4E).
We next analyzed 70 ESCC tissue samples by immunohisto-
chemistry to investigate whether FGF-2 expression levels were
associated with clinicopathological background factors of ESCC pa-
tients. We evaluated FGF-2 expression levels in these tissues
compared with the corresponding nonneoplastic squamous epi-
thelium (Fig. 4F). We divided the site of localization of FGF-2
expression into three parts as follows: cancer stroma, cancer nests,
and both cancer nests and stroma. These three parts were further
categorized as low- and high-intensity groups (Fig. 4F). The high-
intensity group in the cancer stroma exhibited signiﬁcant positive
correlations with the depth of invasion, blood vessel invasion, stage,
and high numbers of inﬁltrating CD163-positive and CD204-
positive macrophages (Table 1). The high-intensity group in the
cancer nests had no signiﬁcant associations with any of the clini-
cal background factors (Table 1).
Wenextperformedaprognostic studyof 69of the70ESCCpatients
(excluding the single patient who was lost to follow-up). A cumu-
lative Kaplan–Meier analysis revealed that the patientswho showed
high-intensitygroupof FGF-2 incancer stromatended tohaveashorter
disease-free survival and overall survival (Suppl. Fig. S4).
Discussion
The results of the present study conﬁrmed that NCAM expres-
sionwas induced in TECM-inducedMacrophage_Ls. The up-regulated
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Fig. 1. Induction of NCAM in peripheral blood monocyte (PBMo)-derived macrophages stimulated with conditioned medium of a TE series ESCC cell line (TECM). PBMos
were treated with 25 ng/mL recombinant human M-CSF for 6 d to induce Macrophage_L and then exposed to the TECM (TE-8, TE-9 and TE-15) for 2 d to induce TAM_Ls.
(A) NCAM mRNA induction in the TAM_Ls was conﬁrmed by RT-PCR (left panel). The results were normalized to GAPDH as a control, and densitometric analysis of bands
was performed with ImageJ (National Institutes of Health, Maryland, USA) (right panel). The results are the mean ± SEM (n = 3, *p < 0.05). (B) NCAM expression levels in the
TAM_Ls were determined by quantitative RT-PCR, compared with those of the Macrophage_Ls, and normalized to GAPDH expression. The results are the mean ± SEM (n = 3,
*p < 0.05). (C) NCAM induction was also conﬁrmed in the TAM_Ls by western blotting (left panel). The results were normalized to β-actin as a control, and densitometric
analysis of bands was performed with the ImageJ (right panel). The results are the mean ± SEM (n = 3, *p < 0.05). (D) NCAM and CD11b expression in Macrophage_Ls and
TAM_Ls. Double immunoﬂuorescence was performed using anti-NCAM (green) plus the macrophage marker anti-CD11b (red). NCAM expression was detectable in TAM_Ls_TE-9
(left panel). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. NCAM ﬂuorescent intensity data were quantiﬁed using ImageJ (right panel). The corrected total cell ﬂu-
orescence (CTCE) was calculated as integrated density − (area of selected cell × mean ﬂuorescence of background reading). The results are the mean ± SEM (n = 3, **p < 0.001).
(E) The localization of NCAM and F-actin in TAM_Ls_TE-9. Immunoﬂuorescence was performed using anti-NCAM (green) in TAM_Ls_TE-9. Nuclei and F-actin were stained
with DAPI (blue) and phalloidin (red), respectively. NCAM and F-actin were co-localized at a part of the lamellipodia (arrowheads). Scale bar, 10 μm. (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 2. The involvement of NCAM in the migration and survival of TAM_Ls via the activation of PI3K-Akt signaling. (A) The effect of TECM on Macrophage_Ls migration and
survival. Transwell migration assay results (left panel): Macrophage_Ls and TAM_L_TE-9were individually detachedwith Accutase and plated on Transwell cell culture inserts
in DMEM supplemented with 1% human AB serum at a density of 1 × 105 cells/well. The cell inserts were set on 24-well plates in serum-free DMEM and then cultured for
24 h. The migrated cells on the underside of the membrane were stained with Diff-Quik and counted. Exposure to TE-9CM signiﬁcantly promoted Macrophage_L migrations.
The results are the mean ± SEM (n = 3, **p < 0.001). Cell survival assay (right panel): Macrophage_Ls and TAM_Ls_TE-9 were individually detached with Accutase and seeded
on 96-well plates at a density of 1 × 104 cells/well. The cell plates were cultured for 24 h in serum-free DMEM. Cell survival activity was assessed by MTS assay. Exposure to
TE-9CM signiﬁcantly promoted Macrophage_L cell survival. The results are the mean ± SEM (n = 3, *p < 0.05, **p < 0.001). (B) Knockdown of NCAM suppressed TAM_L mi-
gration and survival. Macrophage_Lswere transfectedwith siRNA forNCAM (siNCAM) or negative control (NC) for 6 h and then exposed to TE-9CM for 2 d to induce TAM_Ls_TE-
9. Each of these detached cells was subjected to a migration assay and cell survival assay as in (A). The silencing of NCAM signiﬁcantly reduced the migration (left panel) and
survival of TAM_Ls_TE-9 (right panel). The results are themean ± SEM (n = 3, *p < 0.05). (C) The silencing of NCAMsuppressed PI3K-Akt signaling in TAM_Ls_TE-9.Macrophage_Ls
were transfected with 20 nM of NCAM siRNA (siNCAM) or negative control siRNA (NC) for 6 h and exposed to TE-9CM for 2 d to induce TAM_Ls_TE-9. The cells were cultured
in serum-free DMEM for 24 h. The cell lysates were collected and applied to a Proﬁler Human Phosphokinase Array. The silencing of NCAM suppressed PI3K-Akt and p70 S6K
(left panel). The results were normalized to a positive control, and densitometric analysis of bands was performed with the ImageJ (middle and right panels). The results are
themean ± SEM(n = 3, *p < 0.05). (D) The effect of TECMon the PI3K-Akt signaling inMacrophage_Ls. The involvement of PI3K/Akt andErk1/2 signaling between theMacrophage_Ls
and TAM_Ls was assessed by western blotting. Phosphorylation of PI3K-Akt by TECM (TE-9 and TE-15) was detected (left panel). Erk1/2 phosphorylation did not appear to
be stimulated by TECM (TE-8, TE-9 and TE-15). The results were normalized to β-actin as a control and densitometric analysis of bands was performed with the ImageJ
(middle and right panels). The results are the mean ± SEM (n = 3, *p < 0.05). (E) The effect of a selective PI3K inhibitor on the migration and survival of TAM_Ls. Detached
TAM_Ls_TE-9 was pretreated with or without the selective PI3K inhibitor LY294002 (20 μM) for 24 h and then subjected to a migration assay and cell survival assay as in (A).
TAM_Ls_TE-9 migration (left panel) and survival (right panel) were signiﬁcantly inhibited by LY294002. The results are the mean ± SEM (n = 3, *p < 0.05, **p < 0.001).
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Fig. 3. The NCAM/FGFR1 interaction induced a speciﬁc cellular response that was remarkably elicited by FGF-2 in TAM_Ls. (A) Co-expression of NCAM and FGFR1 in TAM_Ls.
The double immunoﬂuorescence examination of TAM_Ls_TE-9 was performed using anti-NCAM (green) and anti-FGFR1 (red) antibodies. NCAM and FGFR1 expression was
co-localized mainly at the cell membranes of TAM_Ls_TE-9 (arrowheads). Scale bar, 10 μm. (B) The silencing of NCAM suppressed FGFR1 expression and phosphorylation in
TAM_Ls. siNCAM or NC transfected with TAM_Ls_TE-9 was cultured for 24 h in serum-free DMEM. The cell lysates were collected, and each sample was analyzed by western
blotting. NCAM silencing also suppressed FGFR1 expression and phosphorylation in TAM_Ls_TE-9 (left panel). The results were normalized to β-actin as a control, and den-
sitometric analysis of bands was performed with ImageJ (middle and right panels). The results are the mean ± SEM (n = 3, **p < 0.001). (C) FGFR1 expression in Macrophage_Ls
and TAM_Ls. Western blotting showed that FGFR1 expression and phosphorylation were up-regulated in TAM_Ls (left panel). The results were normalized to β-actin as a
control, and densitometric analysis of bands was performed with ImageJ (middle and right panels). The results are the mean ± SEM (n = 3, *p < 0.05). (D) The concentration
of FGF-2 protein in the conditioned medium of ESCC cell lines and TAM_Ls. Protein levels were measured by ELISA. The secreted FGF-2 levels in TE-8, TE-9 and TE-15 were
20.58 ± 2.38 pg/mL, 12.74 ± 2.67 pg/mL and 0.98 ± 0.35 pg/mL, respectively. In contrast, the FGF-2 secreted by TAM_Ls was undetectable. The data are the mean ± SEM in
triplicate. (E) PI3K-Akt and MEK1/2-Erk1/2 phosphorylation in TAM_Ls by FGF-2. TAM_Ls_TE-9 was cultured for 24 h in serum-free DMEM in the presence or absence of
recombinant protein (rhFGF-2, 5 ng/mL) and/or selective FGFR1 inhibitor (SU5402, 50 μM). Cells were pretreated with SU5402 1 h before adding rhFGF-2. FGF-2 treatment
activated PI3K-Akt and MEK1/2-Erk1/2 signaling, and a persistent phosphorylation level was maintained up to 1 h in TAM_Ls_TE-9 (upper left panel). TAM_Ls_TE-9 was pre-
treated with SU5402 or untreated for 1 h followed by stimulation with rhFGF-2 for 1 h. rhFGF-2 signiﬁcantly phosphorylated FGFR1, and pretreatment with SU5402 signiﬁcantly
inhibited FGFR1, Akt and Erk1/2 phosphorylation (lower left panel). The results were normalized to β-actin as a control, and densitometric analysis of bands was performed
with ImageJ (right panels). The results are the mean ± SEM (n = 3, *p < 0.05, **p < 0.001). (F) Effect of FGF-2 on TAM_L migration and survivals. Transwell migration assay (left
panel): TAM_Ls_TE-9 was detached with Accutase and plated on Transwell cell culture inserts at a density of 1 × 105 cells/well with DMEM supplemented with 1% human
AB serum in the presence or absence of rhFGF-2 (5 ng/mL) and/or SU5402 (50 μM). Cells were pretreated with SU5402 for 1 h before adding rhFGF-2. The cells were placed
on 24-well plate inserts in serum-free DMEM and then cultured for 24 h. The migrated cells on the underside of the membrane were stained with Diff-Quik and counted.
The migration of TAM_Ls_TE-9 was signiﬁcantly promoted by rhFGF-2. FGF-2-induced TAM_Ls_TE-9 migration was signiﬁcantly inhibited by SU5402, and pretreatment with
SU5402 was not responsive to rhFGF-2. The results are the mean ± SEM (n = 3, *p < 0.05). Cell survival assay (right panel): TAM_Ls_TE-9 was detached with Accutase and
seeded on 96-well plates at a density of 1 × 104 cells/well. The cell plates were cultured for 24 h in serum-free DMEM in the presence or absence of rhFGF-2 (5 ng/mL)
and/or SU5402 (50 μM). Cells were pretreated with SU5402 for 1 h before adding rhFGF-2. Cell survival activity was assessed by MTS assay. The survival of TAM_Ls_TE-9
was signiﬁcantly promoted by rhFGF-2. FGF-2-induced survival of TAM_Ls_TE-9 was signiﬁcantly inhibited by SU5402, and pretreatment with SU5402 was not responsive
to rhFGF-2. The results are presented as the mean ± SEM (n = 3, *p < 0.05). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
Table 1
Expression levels of FGF-2 in ESCC environment and their association with clinicopathological parameters and inﬁltrating macrophage phenotypes.
Number
of cases
Expression of FGF-2a
Stroma p-value Nest p value Stroma
and nest
Stroma
and/or nest
p-value
Low (n = 35) High (n = 35) Low (n = 42) High (n = 28) Low (n = 21) High (n = 49)
Age
<65 33 17 16 N.S. 20 13 N.S. 11 22 N.S.
≥65 37 18 19 22 15 10 27
Histological gradeb
HGIEN + WDSCC 16 11 5 N.S. 8 8 N.S. 5 11 N.S.
MDSCC + PDSCC 54 24 30 34 20 16 38
Depth of tumor invasionb
T1 49 31 18 0.001** 29 20 N.S. 20 29 0.003**
T2 + T3 21 4 17 13 8 1 20
Lymphatic vessel invasionb
Negative 37 22 15 N.S. 20 17 N.S. 14 23 N.S.
Positive 33 13 20 17 11 7 26
Blood vessel invasionb
Negative 43 28 15 0.001** 27 16 N.S. 18 25 0.006**
Positive 27 7 20 15 12 3 24
Lymph node metastasisb
Negative 43 16 17 N.S. 15 18 N.S. 16 17 0.001**
Positive 27 19 18 27 10 5 32
Stagec
0 + I 38 25 13 0.004** 22 16 N.S. 16 22 0.016*
II + III + IV 32 10 22 20 12 5 27
CD68 positive cellsd
Low 35 21 14 N.S. 17 18 N.S. 12 23 N.S.
High 35 14 21 25 10 9 26
CD163 positive cellsd
Low 35 23 12 0.009** 18 17 N.S. 13 22 N.S.
High 35 12 23 24 11 8 27
CD204 positive cellsd
Low 34 26 8 <0.0001*** 17 17 N.S. 15 19 0.012*
High 36 9 27 25 11 6 30
Data were analyzed by χ2-test. p < 0.05 was considered statistically signiﬁcant: *p < 0.05; **p < 0.01; ***p < 0.001.
a The site of localization of FGF-2 expression was divided into three parts as follows: cancer stroma, cancer nests and both cancer nests and stroma. These three parts
were further categorized as low- and high-intensity groups.
b According to the Japanese Classiﬁcation of Esophageal Cancer [26]. HGIEN, high-grade intraepithelial neoplasia; WDSCC, well-differentiated squamous cell carcinoma;
MDSCC, moderately differentiated squamous cell carcinoma; PDSCC, poorly differentiated squamous cell carcinoma. T1a, tumor invades mucosa; T1b, tumor invades sub-
mucosa; T2, tumor invades muscularis propria; T3, tumor invades adventitia.
c According to the TNM classiﬁcation by UICC [27].
d The median values of CD68 positive, CD163 positive or CD204 positive macrophage numbers in cancer nests and stroma within the areas were used to divide the pa-
tients into low- and high-groups.
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NCAM in TAM_Ls was morphologically co-localized with NCAM and
a part of the lamellipodia that is involved in chemotaxis. Another
study showed that stimulation with M-CSF led to lamellipodia
formation in macrophages and induced migration and chemo-
taxis [34]. In adenoid cystic carcinoma cells grown on laminin, NCAM
expression was selectively distributed to the lamellipodia, suggest-
ing its participation in cell migration [35].
Roles of NCAM in intracellular signaling have been reported in
various cell types [36,37]. Shi et al. indicated that NCAM potenti-
ated cellular invasion andmetastasis by activating PKA-PI3K signaling
in melanoma cells [22]. NCAM is also a non-canonical ligand for
FGFR1. NCAM binding is involved in sustained activation and re-
cycling by preventing FGFR1 ubiquitination and degradation [30].
Moreover, a previous study reported that the activation of NCAM-
mediated FGFR1 downstream signaling factors, such as PI3K-Akt and
Erk1/2, is involved in neurite outgrowth and tumor progression
[38–40]. In the present study, the NCAM expression induced TAM_L
migration and survival through PI3K-Akt signaling. NCAM expres-
sion was involved in the retention of the expression level of FGFR1
and its phosphorylation in TAM_Ls. These ﬁndings suggest novel roles
of NCAM in TAMs.
The acquisition of the M2-like phenotype is involved in chemo-
taxis andmacrophage survival [41,42]. A recent study demonstrated
that the M2 polarization of macrophages in the gastric cancer mi-
croenvironment promoted their chemotaxis and survival through
the activation of Akt, Erk1/2 and STAT3 signaling [43]. In the present
study, TECM exposure induced the migration and survival of
Macrophage_Ls through PI3K-Akt signaling. In addition, TECM stim-
ulation up-regulated the expression levels of FGFR1 and its
phosphorylation inMacrophage_Ls. These results indicated thatmac-
rophages acquiredM2-like characters via the up-regulation of NCAM
and FGFR1, resulting in TAMmigration and survival within the tumor
microenvironment of ESCC.
A recent study reported that inhibition of FGF-2-mediated FGFR
signaling could offer a better treatment option for patients with ad-
vanced, relapsed or refractory cancers [44]. FGF-2 is amember of the
FGF family that is expressed in various normal cells. Macrophages
also express and secrete FGF-2 [45,46]. FGF-2 occurs in four isoforms.
The low-molecular-weight isoform(LMWFGF-2,18 kDa)exhibits char-
acteristic autocrine, paracrine and intracrine effects [47]. FGF-2
promotes thechemotaxis andproliferationof endothelial cells through
Erk1/2 signaling, resulting in wound repair [48,49]. The autocrine,
paracrine and intracrine growth promotion of FGF-2/FGFR1 signal-
ing has been conﬁrmed in various tumors [50–53]. In macrophages,
the inductionof vasculogenicmimicry formation inmultiplemyeloma
is involved in the promotion of macrophage chemotaxis through an
FGF-2/FGFR1 paracrine mechanism [54].
In the present study, FGF-2 stimulation induced the migration
and survival of TECM-induced Macrophage_Ls and TE cells. PI3K-
Akt andMEK1/2-Erk1/2 signalingwere activated in TAM_Ls by FGF-2,
and MEK1/2-Erk1/2 signaling was activated in TE cells by FGF-2.
Chernykh et al. reported that FGF-2 was secreted by macrophages
[46], but our present investigation was not able to conﬁrm the se-
cretion of FGF-2. However, our in vitro (Fig. 4D) and in vivo (Fig. 4E)
experiments demonstrated FGF-2 protein expression in TAMs. In ad-
dition, FGF-2 exerts cellular activities through nuclear FGF-2/FGF1
intracrine mechanisms in pancreatic stellate cells [53]. We also con-
ﬁrmed the expression of FGF-2 and FGFR1 in the cytoplasm and
nuclei of TAM_L_TE-9. These data may indicate that FGF-2 pro-
motes the migration and survival of TAM_Ls and ESCC cells though
FGFR1 signaling.
A recent study reported that FGFR1 activating factors, such as
NCAM-derived- and FGF-2-agonists, could offer better therapeutic
targets of neurodegenerative disorders [55]. However, the association
between NCAM-induced FGFR1 and FGF-2-induced FGFR1 signal-
ing remains elusive. The F3 module 2 structure of NCAM binds to
FGFR directly, and FGF-2 coordinates the FGFR signal by having a
structure similar to that F3 module 2 of NCAM [56,57]. Ditlevsen
et al. also demonstrated that NCAM- and FGF-2-mediated FGFR1
signaling shares many common pathways, such as Akt and Erk1/2
[58]. The dramatic divergence between NCAM- and FGF-2-mediated
FGFR1 signaling can be explained by the intracellular traﬃcking of
FGFR1. FGF-2-mediated FGFR1 signaling induces the classical route
of Cbl-mediated ubiquitination followed by lysosomal degrada-
tion, whereas NCAM-mediated FGFR1 signaling promotes FGFR1
stabilization and recycling [30,59]. In addition, Francavilla et al. re-
ported that NCAM and FGF-2 bind to a different tyrosine residue
in FGFR and cause speciﬁc respective responses [30]. In the present
study, both NCAM- and FGF-2-mediated FGFR1 signaling phos-
phorylated Tyr653/654, which is essential for activation of FGFR1
tyrosine kinase activity [60].
Previous studies showed that up-regulated FGF-2 correlated with
a poor prognosis in pancreatic ductal carcinoma and glioma [61,62]
but not in breast cancer [63]. In the present study, we analyzed the
relationship between FGF-2 expression and clinicopathological pa-
rameters in cancer nests and stroma separately because some of the
FGF-2-positive stromal cells expressed CD204 in ESCC. Similar to
the previous report [33], our prognostic analysis showed no prog-
nostic signiﬁcance of the up-regulation of FGF-2 in cancer nests or
stroma. In addition to a clinicopathological correlation, our ﬁndings
Fig. 4. High FGF-2 expression was detected not only in cancer cells but also their surrounding stromal cells of human ESCC tissues, and this expression may activate the
FGF-2/FGFR1 loop for cancer cell migration and survival. (A) FGFR1 expression in the ESCC cell lines. FGFR1 expression levels were detected in all three ESCC cell lines (TE-
8, TE-9 and TE-15) by western blotting. (B) The effect of FGF-2 on MEK1/2-Erk1/2 signaling in the ESCC cell lines. Western blotting (left panel): TE-9 cells were cultured for
24 h with serum-free DMEM in the presence or absence of rhFGF-2 (20 ng/mL) for 1 h and/or SU5402 (50 μM). Cells were pretreated with SU5402 for 1 h before adding
rhFGF-2. rhFGF-2 treatment activated MEK1/2-Erk1/2 in TE-9. Pretreatment with SU5402 suppressed MEK1/2-Erk1/2 signaling in TE-9 cells. PI3K-Akt phosphorylation did
not appear to be stimulated by rhFGF-2 and SU5402 in TE-9. The results were normalized to β-actin as a control and densitometric analysis of bands was performed with
ImageJ (middle and right panels). The results are the mean ± SEM (n = 3, **p < 0.001). (C) FGF-2 promoted ESCC cell survival and migration. The ESCC cell lines were detached
with trypsin-EDTA. The Transwell migration assay (left panel) and cell survival assay (right panel) also followed the same process as that described in Fig. 3F. TE-9 survival
was signiﬁcantly promoted by rhFGF-2 (20 ng/mL). The FGF-2-induced migration and survival of TE-9 were signiﬁcantly inhibited by SU5402 (50 μM), and pretreatment
with SU5402 did not affect the stimulation of FGF-2. The results are the mean ± SEM (n = 3, *p < 0.05, **p < 0.001). (D) FGF-2 expression in Macrophage_Ls and TAM_Ls. A
double immunoﬂuorescence analysis of TAM_Ls_TE-9 was performed using anti-FGF-2 antibody (green) and the M2 macrophage marker anti-CD204 (red) antibody. FGF-2
and CD204 co-expression was detectable in TAM_Ls_TE-9. TAM_Ls_TE-9 expressing FGF-2 also expressed CD204. Nuclei were stained with DAPI (blue). Scale bar, 10 μm. (E)
Cancer cells and cancer stromal cells, including CD204+ TAMs, expressed FGF-2 in human ESCC tissues. Double immunoﬂuorescence was performed using anti-FGF-2 (green)
and anti-CD204 (red) antibodies in human ESCC tissue. FGF-2 was expressed in both cancer nests and cancer stroma, and some of the FGF-2 positive cells were CD204+
macrophages. Arrowheads indicate FGF-2- and CD204-positive macrophages in both the cancer nests and stroma of the human ESCC tissue. Nuclei were stained with DAPI
(blue). Scale bar, 50 μm. (F) Representative FGF-2 immunoreactivity of cancer nests and their surrounding stroma in human ESCC tissues. Typical images of FGF-2 high-
intensity (left panel) and FGF-2 low-intensity (right panel) immunoreactivity in the ESCC tissues. In the tissue with high-intensity FGF-2, both cancer nests and their surrounding
stroma exhibited increased cytoplasmic FGF-2 immunoreactivity compared with the corresponding nonneoplastic squamous epithelium (insets). The intensity of FGF-2 im-
munoreactivity was equal to that of the corresponding nonneoplastic squamous epithelium (insets) in the FGF-2 low-intensity cancer tissue. Scale bar, 50 μm. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
55N. Takase et al. / Cancer Letters 380 (2016) 47–58
revealed for the ﬁrst time an association between up-regulated FGF-2
within cancer stroma and inﬁltrated M2 macrophages. These data
imply that the up-regulation of FGF-2 in stromal cells, including
TAMs, promoted tumor formation through an FGF-2/FGFR1 intracrine
and paracrine loop in TAMs.
In summary, NCAM expression may play roles not only in FGFR1
expression levels but also in the regulation of FGF-2/FGFR1 intracrine
and paracrine mechanisms in TAMs (Fig. 5). These ﬁndings indicate
a novel role of NCAM- and FGF-2-mediated FGFR1 signaling in ESCCs,
including TAMs. Our results suggest that these molecules could
become new biomarkers and could be used in cancer therapy tar-
geted against the progression of ESCC.
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